Publications
LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG)
Vinitsky, A,
Chiang, J,
Bag, AK,
Campagne, O,
Stewart, CF,
Dunphy, P,
Shulkin, B,
Li, Q,
Lin, T,
Hoehn, ME,
Johnson, JN,
Towbin, JA,
Khan, R,
Tatevossian, RG,
Armstrong, GT,
Potter, B,
Conklin, H,
Shearer, T,
Scott, S,
Robinson, GW,
Neuro-Oncology, 2022 Jun; DOI:10.1093/neuonc/noac079.336 LTBK-05. Outcomes of Infants and Young Children with Newly Diagnosed Localized (M0) SHH Medulloblastoma Treated on The NEXT Consortium “Head Start” 4 Protocol
Dhall, G,
Stanek, J,
Blue, M,
Patel, P,
Thomas, D,
Pierson, C,
Tamrazi, B,
Mahadeo, KM,
Fleming, J,
Bell, E,
Miller, K,
Grischow, O,
Liszkay, T,
Coven, S,
Hastings, C,
Tsui, K,
Mazewski, C,
Friedman, G,
Moertel, C,
Hanson, D,
Koschmann, C,
Brock, G,
Wong, K,
Chakravarti, A,
Asgharzadeh, S,
Nelson, MN,
Boue, D,
Biegel, J,
Mardis, E,
Finlay, J,
Neuro-Oncology, 2022 Jun; DOI:10.1093/neuonc/noac079.717 Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population
Karlitz, JJ,
Fendrick, AM,
Bhatt, J,
Coronado, GD,
Jeyakumar, S,
Smith, NJ,
Plescia, M,
Brooks, D,
Limburg, P,
Lieberman, D,
Popul Health Manag, 2022 Jun; DOI:10.1089/pop.2021.0185 BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
Hussain, MHA,
Kocherginsky, M,
Agarwal, N,
Zhang, J,
Adra, N,
Paller, CJ,
Picus, J,
Reichert, ZR,
Szmulewitz, RZ,
Tagawa, ST,
Whang, YE,
Dreicer, R,
Kuzel, T,
Bazzi, L,
Gerke, TA,
Daignault-Newton, S,
Chinnaiyan, A,
Antonarakis, ES,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.5018 Unpacking low-value castration practices using behavior specification to guide de-implementation in prostate cancer care.
Skolarus, TA,
Forman, J,
Sparks, JB,
Metreger, T,
Hawley, ST,
Caram, MV,
Dossett, LA,
Larkin, A,
Paniagua Cruz, A,
Makarov, DV,
Leppert, JT,
Shelton, JB,
Stensland, KD,
Hollenbeck, BK,
Shahinian, V,
Wittmann, DA,
Deolankar, V,
Sriram, S,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.e17055 Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma
Kurokawa, R,
Kurokawa, M,
Baba, A,
Ota, Y,
Kim, J,
Capizzano, A,
Srinivasan, A,
Moritani, T,
Eur Radiol, 2022 Jun; DOI:10.1007/s00330-021-08476-7 GATA3 expression in pulmonary mucinous adenocarcinoma presenting as a distant metastasis: A case report
Shaker, N,
Hanline, CC,
Tynski, IM,
Tynski, Z,
Amadi, CC,
Parwani, A,
Shilo, K,
Human Pathology Reports, 2022 Jun; DOI:10.1016/j.hpr.2022.300642 Risk of obstructive sleep apnea after treatment of head and neck squamous cell carcinoma: a cross-sectional study
Gavidia, R,
Dunietz, GL,
O'Brien, LM,
Schütz, SG,
Spector, ME,
Swiecicki, PL,
Chervin, RD,
J Clin Sleep Med, 2022 Jun; DOI:10.5664/jcsm.9954 Increased incidence of immune-mediated myocarditis in advanced skin malignancies treated with immune checkpoint inhibitors in the COVID-19 era.
Gradone, A,
Ma, VT,
Fecher, LA,
Yentz, SE,
Vasbinder, A,
Hayek, SS,
Lao, CD,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.2664 Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature
Kurokawa, M,
Kurokawa, R,
Capizzano, AA,
Baba, A,
Ota, Y,
Pinarbasi, E,
Johnson, T,
Srinivasan, A,
Moritani, T,
Neuroradiology, 2022 Jun; DOI:10.1007/s00234-021-02879-5 Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.
Kilari, D,
Szabo, A,
Ghatalia, P,
Rose, TL,
Dong, H,
Weise, N,
Zhuang, TZ,
Alloghbi, A,
Jain, RK,
Alva, AS,
Tripathi, A,
Basu, A,
Davis, NB,
Brundage, J,
Emamekhoo, H,
Zakharia, Y,
Koshkin, VS,
Bilen, MA,
Heath, EI,
McKay, RR,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.4545 Cost-effectiveness of mt-sDNA versus mailed FIT outreach for Medicare Advantage enrollees using the CRC-AIM microsimulation model.
Bhatt, J,
Chen, JV,
Vahdat, V,
Fendrick, A,
Lieberman, DA,
Brooks, D,
Ozbay, AB,
Karlitz, JJ,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.e18827 ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
Hamilton, EP,
Schott, AF,
Nanda, R,
Lu, H,
Keung, CF,
Gedrich, R,
Parameswaran, J,
Han, HS,
Hurvitz, SA,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.tps1120 Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.
Odia, Y,
Koschmann, CJ,
Tarapore, R,
Allen, J,
Zaky, WT,
Hall, MD,
Daghistani, D,
Khatib, Z,
Aguilera, D,
MacDonald, TJ,
de Blank, P,
McGovern, SL,
Mueller, S,
Kline, C,
Vitanza, NA,
Allen, JE,
Gardner, SL,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.tps2082 Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need
Tosoian, JJ,
Singhal, U,
Davenport, MS,
Wei, JT,
Montgomery, JS,
George, AK,
Salami, SS,
Mukundi, SG,
Siddiqui, J,
Kunju, LP,
Tooke, BP,
Ryder, CY,
Dugan, SP,
Chopra, Z,
Botbyl, R,
Feng, Y,
Sessine, MS,
Eyrich, NW,
Ross, AE,
Trock, BJ,
Tomlins, SA,
Palapattu, GS,
Chinnaiyan, AM,
Niknafs, YS,
Morgan, TM,
Urology, 2022 Jun; DOI:10.1016/j.urology.2021.11.033 A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.
Federico, SM,
Naranjo, A,
Zhang, F,
Marachelian, A,
Desai, AV,
Shimada, H,
Braunstein, SE,
Tinkle, CL,
Yanik, GA,
Asgharzadeh, S,
Sondel, PM,
Yu, AL,
Acord, M,
Parisi, MT,
Shulkin, BL,
DuBois, SG,
Bagatell, R,
Park, JR,
Furman, WL,
Shusterman, S,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.10003 Development and Validation of Dynamic Multivariate Prediction Models of Sexual Function Recovery in Patients with Prostate Cancer Undergoing Radical Prostatectomy: Results from the MUSIC Statewide Collaborative.
Agochukwu-Mmonu, N,
Murali, A,
Wittmann, D,
Denton, B,
Dunn, RL,
Montie, J,
Peabody, J,
Miller, D,
Singh, K,
Michigan Urological Surgery Improvement Collaborative, Array,
Eur Urol Open Sci, 2022 Jun; DOI:10.1016/j.euros.2022.03.009 Focal radiation with pulsed systemic therapy of abiraterone, androgen deprivation therapy (ADT), olaparib towards castration-sensitive oligometastatic prostate cancer (FAALCON Trial).
Reichert, ZR,
Vaishampayan, UN,
Caram, MV,
Alumkal, JJ,
Alva, AS,
Palmbos, P,
Yentz, SE,
Smith, DC,
Hearn, JWD,
Dess, RT,
Jackson, WC,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.tps5113 Comparison of simulated outcomes between stool- and blood-based colorectal cancer screening tests.
Fendrick, A,
Vahdat, V,
Chen, JV,
Lieberman, DA,
Karlitz, JJ,
Limburg, PJ,
Ozbay, AB,
Kisiel, JB,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.10529 Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy.
Ma, VT,
Agrawal, YN,
Fecher, LA,
Lao, CD,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.9530 Disparities in Thyroid Care
Chen, DW,
Yeh, MW,
Endocrinol Metab Clin North Am, 2022 Jun; DOI:10.1016/j.ecl.2021.11.017 Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group
Crane, JN,
Xue, W,
Qumseya, A,
Gao, Z,
Arndt, CAS,
Donaldson, SS,
Harrison, DJ,
Hawkins, DS,
Linardic, CM,
Mascarenhas, L,
Meyer, WH,
Rodeberg, DA,
Rudzinski, ER,
Shulkin, BL,
Walterhouse, DO,
Venkatramani, R,
Weiss, AR,
Pediatr Blood Cancer, 2022 Jun; DOI:10.1002/pbc.29644 Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
Tawbi, HA,
Hodi, FS,
Lipson, EJ,
Schadendorf, D,
Ascierto, PA,
Matamala, L,
Salman, P,
Gutiérrez, EC,
Rutkowski, P,
Gogas, H,
Lao, CD,
Janoski De Menezes, J,
Dalle, S,
Arance, AM,
Grob, J-J,
Keidel, S,
Jonczak, K,
Sobiesk, AM,
Dolfi, S,
Long, GV,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.9505 Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.
Gorin, MA,
Rowe, SP,
Pienta, KJ,
Carroll, PR,
Pouliot, F,
Probst, S,
Saperstein, L,
Preston, M,
Alva, AS,
Patnaik, A,
Stambler, N,
Siegel, BA,
Morris, MJ,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.5024 Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).
Hwang, C,
Henderson, N,
Cackowski, FC,
Pilling, A,
Jang, A,
Rothstein, S,
Labriola, M,
Park, JJ,
Ghose, A,
Bilen, MA,
Kilari, D,
Tripathi, A,
Garje, R,
Koshkin, VS,
Schweizer, MT,
Armstrong, AJ,
McKay, RR,
Dorff, TB,
Alva, AS,
Barata, PC,
Journal of Clinical Oncology, 2022 Jun; DOI:10.1200/jco.2022.40.16_suppl.5013 